Hyponatraemia and cirrhosis

Gastroenterology Report

Volumn 2, Issue 1, 2014, Pages 21-26

  Gianotti, Robert J ^a   Cardenas, Andres ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cirrhosis; End stage liver disease; Hyponatraemia; Vaptans

Indexed keywords

EID: 84908071631     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/got037     Document Type: Review

References (42)

1. Angeli P, Wong F, Watson H et al. CAPPS Investigators. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006;44:1535-42.
2. Ahluwalia V, Wade JB, Thacker L et al. Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J Hepatol 2013; 59:467-73.
3. Biggins SW, Rodriguez HJ, Bacchetti P et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41:32-39.
4. AdroguéHJ and Madias NE. Hyponatremia. N Engl J Med 2000;342: 1581-89.
5. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
6. Schrier RW. Water and sodium retention in edematous disorders: Role of vasopressin and aldosterone. Am J Med 2006;119 (7 Suppl 1), S47-53.
7. Ginès P and Cárdenas A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008;28:43-58.
8. Iwakiri Y. The molecules: Mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007;41 (Suppl 3), S288-94
9. Nielsen S, Frokiaer J, Marples D et al. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002;82:205-44.
10. Ginès P and Guevara M. Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management. Hepatology 2008;48: 1002-10.
11. Arroyo V, Rodés J, Gutiérrez-Lizárraga MA et al. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976;21:249-56.
12. Kim WR, Biggins SW, Kremers WK et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-26.
13. Londono MC, Cárdenas A, Guevara M et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007;56:1283-90.
14. Solà E, Watson H, Graupera I et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol 2012;57:1199-206.
15. Guevara M, Baccaro ME, Torre A et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 2009;104: 1382-89.
16. Riggio O, Angeloni S, Salvatori FM et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol 2008;103:2738-46.
17. Córdoba J, García-Martinez R and Simón-Talero M. Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence. Metab Brain Dis 2010;25:73-80.
18. Häussinger D and Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008;57:1156-65.
19. Häussinger D, Laubenberger J, vom Dahl S et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 1994;107:1475-80.
20. Follo A, Llovet JM, Navasa M et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-1501.
21. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9.
22. Pereira G, Guevara M, Fagundes C et al. Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J Hepatol 2012;56:1040-46.
23. Pugliese R, Fonseca EA, Porta G et al. Ascites and serum sodium are markers of increased waiting list mortality in children with chronic liver failure. Hepatology2013, Oct 7;Epub ahead of print.
24. Yun BC, Kim WR, Benson JT et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 2009;49:1610-15.
25. Londono M, Guevara M, Rimola A et al. Hyponatremia impairs early post-transplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006;130:1135-43.
26. Dawwas MF, Lewsey JD, Neuberger JM et al. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl 2007;13:1115-24.
27. Runyon BA. AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49:2087-107.
28. Verbalis JG, Goldsmith SR, Greenberg A et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120 (11 Suppl 1), S1-21.
29. Jalan R, Mookerjee R, Cheshire L et al. Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial. J Hepatol 2007;46 (S1), S95.
30. McCormick PA, Mistry P, Kaye G et al. Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut 1990;31:204-7.
31. Gerbes AL, Gülberg V, Ginès P et al. VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124:933-39.
32. Wong F, Blei AT, Blendis LM et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182-91.
33. Schrier R W, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112.
34. Cárdenas A, Ginès P, Marotta P et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 2012;56:571-78.
35. Torres VE, Chapman AB, Devuyst O et al. TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 1012;367:2407-18.
36. Ginès P, Wong F, Watson H et al. HypoCAT Study Investigators. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008;48:204-13.
37. Soupart A, Coffernils M, Couturier B et al. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol 2012;7:742-47.
38. Gines P, Wong F and Watson H. Long-term improvement of serum sodium by the v-receptor antagonist satavaptan in patients with cirrhosis and hyponatraemia. J Hepatol 2007;46 (Suppl 1), S41.
39. Dahl E, Gluud LL, Kimer N et al. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatremia. Aliment Pharmacol Ther 2012;36: 619-26.
40. Wong F, Watson H, Gerbes A et al. Satavaptan Investigators Group. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012; 61:108-16.
41. Watson H, Jepsen P, Wong F et al. Satavaptan treatment for ascites in patients with cirrhosis: A meta-analysis of effect on hepatic encephalopathy development. Metab Brain Dis 2013;28: 301-5.
42. Sakaida I, Kawazoe S, Kajimura K et al. ASCITES-DOUBLEBLIND Study Group. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res2013, Apr 3 Epub ahead of print